MARKET

HBIO

HBIO

Harvard Biosci
NASDAQ
2.260
+0.120
+5.61%
After Hours: 2.260 0 0.00% 16:24 12/06 EST
OPEN
2.140
PREV CLOSE
2.140
HIGH
2.260
LOW
2.120
VOLUME
277.60K
TURNOVER
--
52 WEEK HIGH
5.56
52 WEEK LOW
1.990
MARKET CAP
98.57M
P/E (TTM)
-6.8860
1D
5D
1M
3M
1Y
5Y
1D
Harvard Bioscience files $100M mixed securities shelf
TipRanks · 1d ago
HARVARD BIOSCIENCE INC FILES FOR MIXED SHELF OF UP TO $100 MLN - SEC FILING
Reuters · 1d ago
Weekly Report: what happened at HBIO last week (1125-1129)?
Weekly Report · 6d ago
Weekly Report: what happened at HBIO last week (1118-1122)?
Weekly Report · 11/25 09:50
Weekly Report: what happened at HBIO last week (1111-1115)?
Weekly Report · 11/18 09:49
Weekly Report: what happened at HBIO last week (1104-1108)?
Weekly Report · 11/11 09:54
Based on the provided financial report article, the title of the article is likely: "10-Q: Harvard Bioscience, Inc. (HBIO) Q3 2024 Earnings Report" This title is inferred based on the following information: * The file name "0001171843-24-006181hbio20240930_10q.htm" suggests that it is a 10-Q filing with the Securities and Exchange Commission (SEC) for Harvard Bioscience, Inc. (HBIO) for the quarter ending September 30, 2024. * The content of the article appears to be a quarterly earnings report for HBIO, including financial statements, notes, and other relevant information. * The title is consistent with the typical format of SEC filings, which typically include the company name, the type of filing (10-Q), and the filing date.
Press release · 11/09 01:04
Harvard Bioscience Reveals Q3 2024 Financial Results
TipRanks · 11/08 04:57
More
About HBIO
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.

Webull offers Harvard Bioscience, Inc. stock information, including NASDAQ: HBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HBIO stock methods without spending real money on the virtual paper trading platform.